Skip to content
The Chat Archive
gemini-2.5-pro-exp-03-25-wo-search· Google LMArena Search Arena 24K

Who owns the rights to linzess, Abbvie or Ironwood? What happens to Ironwood’s rights to…

  1. User

    Who owns the rights to linzess, Abbvie or Ironwood? What happens to Ironwood’s rights to Linzess when the product goes generic?

  2. Assistant

    Okay, let's break down the rights situation for Linzess (linaclotide):

    1. Who Owns the Rights (Primarily in the US)?

      • It's a collaboration, not a simple ownership by one company.
      • Ironwood Pharmaceuticals invented Linzess and holds the fundamental intellectual property (patents).
      • AbbVie (through its acquisition of Allergan) is Ironwood's commercialization partner in North America (specifically the United States).
      • How it works: Ironwood and AbbVie co-develop and co-commercialize Linzess in the US. They share the net profits and losses roughly 50/50 according to their agreement.
      • Outside the US: Ironwood has partnered with other companies (like Astellas in Japan and AstraZeneca in China) for rights in different territories.

      In summary: For the significant US market, both Ironwood and AbbVie effectively share the rights and the economics based on their collaboration agreement. Ironwood is the originator, AbbVie is the US commercial partner.

    2. What Happens to Ironwood's Rights When Linzess Goes Generic?

      • "Going generic" means the primary patents protecting Linzess expire or are successfully challenged, allowing other companies to manufacture and sell generic versions (linaclotide).
      • Impact on Revenue: When generics enter the market, they typically do so at a much lower price. This forces the branded product (Linzess) to lower its price and rapidly lose market share. Consequently, the total revenue and profit generated by branded Linzess decrease dramatically.
      • Impact on Ironwood's Rights/Economics:
        • Ironwood's contractual rights under the collaboration agreement with AbbVie don't automatically disappear just because a generic exists. They still technically "hold" their share of the rights to the branded product as long as the agreement is active and patents are legally valid (even if facing competition).
        • However, the economic value derived from those rights plummets. Since Ironwood's income from Linzess in the US is based on a share of the profits, and those profits will shrink drastically due to generic competition, Ironwood's revenue stream from branded Linzess will significantly decline.
        • Patent expiry is the key trigger. Once the relevant patents expire (expected timeframe is currently around 2029-2032, though this can be subject to litigation and patent term extensions), generic entry becomes possible.

      In summary: When Linzess goes generic, Ironwood retains its contractual position alongside AbbVie for the branded product, but the financial return from those rights will be severely reduced due to competition significantly eroding branded Linzess sales and profits. The underlying patents expiring are the key event enabling generic competition.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.